40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study
Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) Jg. 385; H. 9974; S. 1206 - 1218 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
28.03.2015
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival.
In this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971–2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971–72, 1980–81, 1990–91, 2000–01, 2005–06, and 2010–11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75–99 years) and youngest (15–44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971.
The overall index of net survival increased substantially during the 40-year period 1971–2011, both in England and in Wales. For patients diagnosed in 1971–72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75–99 years) was persistently lower than for the youngest (15–44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people.
These findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved.
Cancer Research UK. |
|---|---|
| AbstractList | Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival.BACKGROUNDAssessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival.In this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971-2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971-72, 1980-81, 1990-91, 2000-01, 2005-06, and 2010-11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75-99 years) and youngest (15-44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971.METHODSIn this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971-2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971-72, 1980-81, 1990-91, 2000-01, 2005-06, and 2010-11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75-99 years) and youngest (15-44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971.The overall index of net survival increased substantially during the 40-year period 1971-2011, both in England and in Wales. For patients diagnosed in 1971-72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75-99 years) was persistently lower than for the youngest (15-44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people.FINDINGSThe overall index of net survival increased substantially during the 40-year period 1971-2011, both in England and in Wales. For patients diagnosed in 1971-72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75-99 years) was persistently lower than for the youngest (15-44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people.These findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved.INTERPRETATIONThese findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved.Cancer Research UK.FUNDINGCancer Research UK. Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival. In this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971–2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971–72, 1980–81, 1990–91, 2000–01, 2005–06, and 2010–11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75–99 years) and youngest (15–44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971. The overall index of net survival increased substantially during the 40-year period 1971–2011, both in England and in Wales. For patients diagnosed in 1971–72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75–99 years) was persistently lower than for the youngest (15–44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people. These findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved. Cancer Research UK. Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival. Methods In this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971-2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971-72, 1980-81, 1990-91, 2000-01, 2005-06, and 2010-11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75-99 years) and youngest (15-44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971. Findings The overall index of net survival increased substantially during the 40-year period 1971-2011, both in England and in Wales. For patients diagnosed in 1971-72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75-99 years) was persistently lower than for the youngest (15-44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people. Interpretation These findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved. Funding Cancer Research UK. Summary Background Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the overall effectiveness of the health system, alongside trends in incidence and mortality. For this purpose, we aimed to provide a unique measure of cancer survival. Methods In this observational study, we analysed trends in survival with population-based data for 7·2 million adults diagnosed with a first, primary, invasive malignancy in England and Wales during 1971–2011 and followed up to the end of 2012. We constructed a survival index for all cancers combined using data from the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit. The index is designed to be independent of changes in the age distribution of patients with cancer and of changes in the proportion of lethal cancers in each sex. We analysed trends in the cancer survival index at 1, 5, and 10 years after diagnosis for the selected periods 1971–72, 1980–81, 1990–91, 2000–01, 2005–06, and 2010–11. We also estimated trends in age-sex-adjusted survival for each cancer. We define the difference in net survival between the oldest (75–99 years) and youngest (15–44 years) patients as the age gap in survival. We evaluated the absolute change (%) in the age gap since 1971. Findings The overall index of net survival increased substantially during the 40-year period 1971–2011, both in England and in Wales. For patients diagnosed in 1971–72, the index of net survival was 50% at 1 year after diagnosis. 40 years later, the same value of 50% was predicted at 10 years after diagnosis. The average 10% survival advantage for women persisted throughout this period. Predicted 10-year net survival adjusted for age and sex for patients diagnosed between 2010 and 2011 ranged from 1·1% for pancreatic cancer to 98·2% for testicular cancer. Net survival for the oldest patients (75–99 years) was persistently lower than for the youngest (15–44 years), even after adjustment for the much higher mortality from causes other than cancer in elderly people. Interpretation These findings support substantial increases in both short-term and long-term net survival from all cancers combined in both England and Wales. The net survival index provides a convenient, single number that summarises the overall patterns of cancer survival in any one population, in each calendar period, for young and old men and women and for a wide range of cancers with very disparate survival. The persistent sex difference is partly due to a more favourable cancer distribution in women than men. The very wide differences in survival for different cancers, and the persistent age gap in survival, suggest the need for renewed efforts to improve cancer outcomes. Future monitoring of the cancer survival index will not be possible unless the current crisis of public concern about sharing of individual data for public health research can be resolved. Funding Cancer Research UK. |
| Author | Rachet, Bernard Quaresma, Manuela Coleman, Michel P |
| Author_xml | – sequence: 1 givenname: Manuela surname: Quaresma fullname: Quaresma, Manuela email: manuela.quaresma@lshtm.ac.uk organization: Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 2 givenname: Michel P surname: Coleman fullname: Coleman, Michel P organization: Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 3 givenname: Bernard surname: Rachet fullname: Rachet, Bernard organization: Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25479696$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkd1qFDEUx4NU7Lb6CErAmwqO5sxHsqOoSKkfUPBCRe9CNjmpWWeTNZlZ3DvfwSfxlXwSM7tbCwtSLybDTH7nl5PzPyIHPngk5C6wR8CAP37PoGYFFxU_gfoBh6rlRXuDTKAWddHU4vMBmfxFDslRSnPGWM1Zc4sclhloecsn5Fcm1qgi7SN6k6jzVPm8GvxOg6VpiCu3Uh21IVLVdVQrrzEmqsNi5jyaTJsrSpn5kPr8d4Nf4HY3q8ZvVPrLrn485sxfdOP2-HxSHaaHFFoBv3_8LBnAE6roMiyHTvUu-GKmUramfjDr2-SmVV3CO7v3Mfn46uzD6Zvi_N3rt6cvzwvNoekLY61u0TZVbY2FGoXQaLlSbGrbVlRCszwomAFT2JpKMDu1zVTlufAKoBKmOiYnW-8yhm8Dpl4uXNLY5aYxDEkCF1CWJRMio_f30HkYos_dZYqLUgBvR-rejhpmCzRyGd1CxbW8DCMDT7eAjiGliFZq12_u30flOglMjtHLTfRyzFVCLTfRyzZXN3vVlwdcV_diW4d5mCuHUSbtMKdkXETdSxPctYbnewbdOe-06r7iGtPVLGQqJdtKRgfUG8MoePZvwX808AfmOO3m |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1038_s41598_017_09833_7 crossref_primary_10_1186_s40880_016_0135_x crossref_primary_10_3390_jcm11051195 crossref_primary_10_3389_fcvm_2022_927769 crossref_primary_10_1016_j_ijrobp_2016_07_022 crossref_primary_10_1136_bmjopen_2017_019758 crossref_primary_10_1007_s11845_020_02231_5 crossref_primary_10_1038_s41408_023_00877_9 crossref_primary_10_1097_MOG_0000000000000321 crossref_primary_10_7861_clinmed_2023_GA1 crossref_primary_10_1136_bmjopen_2015_010817 crossref_primary_10_1016_j_radonc_2018_05_029 crossref_primary_10_1007_s11864_019_0644_3 crossref_primary_10_1016_j_surge_2021_08_007 crossref_primary_10_1136_bmjopen_2018_021796 crossref_primary_10_1245_s10434_016_5515_6 crossref_primary_10_1038_bjc_2017_127 crossref_primary_10_5812_ijcm_100730 crossref_primary_10_1186_s13063_024_08062_4 crossref_primary_10_1136_ijgc_2018_000039 crossref_primary_10_1016_S2352_3026_15_00155_6 crossref_primary_10_1016_j_ihj_2016_01_022 crossref_primary_10_1136_heartjnl_2018_313726 crossref_primary_10_3892_ol_2022_13275 crossref_primary_10_3238_PersDia_2025_06_27_01 crossref_primary_10_3390_healthcare12191975 crossref_primary_10_1007_s00104_021_01561_z crossref_primary_10_1016_j_pan_2018_10_010 crossref_primary_10_1007_s00701_022_05373_w crossref_primary_10_1136_bmj_p2292 crossref_primary_10_1093_biostatistics_kxy008 crossref_primary_10_1136_gutjnl_2016_312695 crossref_primary_10_1016_j_jaccao_2024_05_015 crossref_primary_10_1007_s10549_017_4514_z crossref_primary_10_1016_j_hfc_2019_11_002 crossref_primary_10_1186_s12885_019_6004_7 crossref_primary_10_1007_s00228_019_02801_2 crossref_primary_10_1093_bmb_ldaf014 crossref_primary_10_1136_bmjopen_2023_078595 crossref_primary_10_1016_j_rbmo_2019_06_001 crossref_primary_10_1016_j_lpm_2019_02_025 crossref_primary_10_1016_j_clon_2021_10_006 crossref_primary_10_1111_ecc_13500 crossref_primary_10_15252_embr_202356964 crossref_primary_10_1038_s41598_023_42793_9 crossref_primary_10_1186_s12885_022_09639_5 crossref_primary_10_3171_2016_9_FOCUS16332 crossref_primary_10_1093_ndt_gfae046 crossref_primary_10_1007_s11892_018_0992_6 crossref_primary_10_1186_s12967_016_1037_z crossref_primary_10_1155_2022_1617989 crossref_primary_10_3389_fcvm_2021_624028 crossref_primary_10_1007_s00761_023_01382_1 crossref_primary_10_1186_s12913_022_08610_1 crossref_primary_10_1093_eurheartj_ehaf100 crossref_primary_10_1530_ERC_16_0118 crossref_primary_10_1038_s41416_021_01573_w crossref_primary_10_1084_jem_20210911 crossref_primary_10_1089_jayao_2019_0047 crossref_primary_10_1595_205651320X15954136194837 crossref_primary_10_3389_fmedt_2023_1219897 crossref_primary_10_1155_2021_6676666 crossref_primary_10_1186_s12910_024_01146_5 crossref_primary_10_7759_cureus_14711 crossref_primary_10_1002_mco2_431 crossref_primary_10_1097_MPA_0000000000002119 crossref_primary_10_1111_febs_15134 crossref_primary_10_1016_j_jgo_2019_01_018 crossref_primary_10_1017_S0007114516001859 crossref_primary_10_1097_MD_0000000000027784 crossref_primary_10_1038_s41419_021_03856_9 crossref_primary_10_1016_j_envint_2021_106671 crossref_primary_10_1080_09638288_2022_2134468 crossref_primary_10_37349_etat_2025_1002314 crossref_primary_10_1097_CM9_0000000000003419 crossref_primary_10_1136_ejhpharm_2022_003377 crossref_primary_10_1016_j_canlet_2021_01_024 crossref_primary_10_1016_j_pan_2021_05_299 crossref_primary_10_1007_s00520_016_3485_7 crossref_primary_10_1200_JCO_2015_64_3536 crossref_primary_10_2196_13566 crossref_primary_10_3390_cancers12010218 crossref_primary_10_1038_bjc_2016_246 crossref_primary_10_1016_j_jff_2022_104958 crossref_primary_10_1245_s10434_015_4937_x crossref_primary_10_1016_j_lanepe_2025_101385 crossref_primary_10_1016_j_biopha_2018_10_084 crossref_primary_10_1136_bmjopen_2018_024627 crossref_primary_10_1155_2021_8054817 crossref_primary_10_1038_s43018_021_00326_1 crossref_primary_10_1016_j_annepidem_2018_02_008 crossref_primary_10_1038_s41419_017_0062_z crossref_primary_10_1038_nrclinonc_2016_109 crossref_primary_10_1093_bjsopen_zrac004 crossref_primary_10_1177_2399202618786932 crossref_primary_10_1016_j_critrevonc_2020_102989 crossref_primary_10_1097_SPC_0000000000000291 crossref_primary_10_1002_jcp_26892 crossref_primary_10_2147_CMAR_S294099 crossref_primary_10_1016_j_hpb_2020_01_005 crossref_primary_10_1038_bjc_2014_596 crossref_primary_10_1136_bmjopen_2017_020313 crossref_primary_10_1136_jmedgenet_2020_107399 crossref_primary_10_1016_j_amjmed_2016_10_017 crossref_primary_10_1186_s12885_024_12761_1 crossref_primary_10_1016_j_ejphar_2023_175869 crossref_primary_10_1097_AS9_0000000000000536 crossref_primary_10_1016_j_pan_2015_12_180 crossref_primary_10_3892_ol_2018_9766 crossref_primary_10_3310_nihropenres_13773_1 crossref_primary_10_1016_j_gande_2025_05_004 crossref_primary_10_1186_s12885_015_1865_x crossref_primary_10_3389_fgene_2022_959832 crossref_primary_10_1007_s11864_023_01094_z crossref_primary_10_1080_10926488_2019_1611723 crossref_primary_10_1186_s13046_019_1088_0 crossref_primary_10_1097_SPC_0000000000000289 crossref_primary_10_1002_ejhf_2818 crossref_primary_10_1038_s41388_022_02529_x crossref_primary_10_1097_MPA_0000000000001691 crossref_primary_10_1245_s10434_020_09200_3 crossref_primary_10_3892_etm_2021_10651 crossref_primary_10_1177_1708538120902653 crossref_primary_10_1002_jhbp_621 crossref_primary_10_3399_BJGPO_2024_0064 crossref_primary_10_1371_journal_pone_0211268 crossref_primary_10_1093_ije_dyab082 crossref_primary_10_1002_cam4_4143 crossref_primary_10_1007_s11764_015_0466_7 crossref_primary_10_1038_s41443_020_0260_6 crossref_primary_10_1177_2050640620938987 crossref_primary_10_1007_s11033_020_05817_5 crossref_primary_10_4103_jcrt_jcrt_1778_21 crossref_primary_10_1016_j_amepre_2019_10_001 crossref_primary_10_1016_j_ejps_2020_105355 crossref_primary_10_1186_s12955_017_0670_4 crossref_primary_10_1002_gcc_22932 crossref_primary_10_3892_ol_2019_10041 crossref_primary_10_3892_ol_2019_10281 crossref_primary_10_1007_s10926_018_9758_x crossref_primary_10_1158_1078_0432_CCR_21_1020 crossref_primary_10_1016_j_jbior_2019_100658 crossref_primary_10_1016_j_hpb_2017_05_009 crossref_primary_10_1186_s13613_016_0151_7 crossref_primary_10_1093_eurjpc_zwae137 crossref_primary_10_3748_wjg_v21_i26_7988 crossref_primary_10_1158_0008_5472_CAN_17_3841 crossref_primary_10_1245_s10434_020_09208_9 crossref_primary_10_7748_cnp_2018_e1403 crossref_primary_10_3390_life13020565 crossref_primary_10_4155_ppa_2019_0012 crossref_primary_10_1097_j_pain_0000000000000872 crossref_primary_10_1002_ejhf_1847 crossref_primary_10_1136_bmjopen_2019_034299 crossref_primary_10_1158_0008_5472_CAN_20_4125 crossref_primary_10_1186_s12951_022_01610_7 crossref_primary_10_3390_cancers16051056 crossref_primary_10_1002_1878_0261_13012 crossref_primary_10_1177_10732748221084853 crossref_primary_10_1186_s12877_022_03060_0 crossref_primary_10_1016_S0140_6736_15_60606_7 crossref_primary_10_1016_j_jaccao_2024_07_010 crossref_primary_10_1016_j_canep_2022_102230 crossref_primary_10_1002_jso_27613 crossref_primary_10_1182_blood_2020007338 crossref_primary_10_1016_j_fertnstert_2022_03_004 crossref_primary_10_1016_j_tice_2020_101479 crossref_primary_10_1016_j_jaccao_2023_05_008 crossref_primary_10_3390_healthcare13172214 crossref_primary_10_1093_rap_rkaa016 crossref_primary_10_1007_s00520_024_08624_x crossref_primary_10_1177_2055102919832234 crossref_primary_10_1007_s00592_019_01447_x crossref_primary_10_1080_08870446_2021_1956494 crossref_primary_10_1111_1468_0009_12358 crossref_primary_10_1038_s43018_023_00619_7 crossref_primary_10_1186_s12935_024_03392_4 crossref_primary_10_1007_s11523_018_0578_x crossref_primary_10_1002_cam4_4697 crossref_primary_10_3892_or_2016_4865 crossref_primary_10_4240_wjgs_v17_i1_100910 crossref_primary_10_1016_j_drudis_2018_01_037 crossref_primary_10_1007_s00125_022_05854_8 crossref_primary_10_1016_j_amjmed_2021_01_031 crossref_primary_10_1093_ageing_afad043 crossref_primary_10_12968_bjon_2024_0056 crossref_primary_10_1111_bcp_15011 crossref_primary_10_1111_hex_13136 crossref_primary_10_1177_15347354211012749 crossref_primary_10_1016_j_radonc_2019_08_025 crossref_primary_10_1158_0008_5472_CAN_18_2244 crossref_primary_10_3389_fphar_2022_906211 crossref_primary_10_1016_j_lungcan_2019_05_026 crossref_primary_10_3390_cancers14102441 crossref_primary_10_1016_j_canep_2024_102576 crossref_primary_10_1016_j_compbiomed_2022_106411 crossref_primary_10_1016_j_conb_2017_06_008 crossref_primary_10_1136_bmjopen_2017_018015 crossref_primary_10_1186_s12885_022_09212_0 crossref_primary_10_1186_s12935_021_02439_0 crossref_primary_10_3389_fmed_2021_668697 crossref_primary_10_1016_j_hlc_2023_11_017 crossref_primary_10_1016_j_phrs_2019_104327 crossref_primary_10_1186_s12885_018_4947_8 crossref_primary_10_1093_jrr_rrab021 crossref_primary_10_1136_bmjopen_2020_045698 crossref_primary_10_1016_j_lungcan_2023_107181 crossref_primary_10_1080_17437199_2024_2336014 crossref_primary_10_1016_S0140_6736_15_60571_2 crossref_primary_10_3892_mmr_2018_8502 crossref_primary_10_1186_s12874_021_01465_w crossref_primary_10_1002_pon_4569 crossref_primary_10_1186_s12885_021_08578_x crossref_primary_10_1158_0008_5472_CAN_15_1790 crossref_primary_10_1097_JCMA_0000000000000615 crossref_primary_10_1371_journal_pdig_0000920 crossref_primary_10_1186_s40359_023_01355_4 crossref_primary_10_12968_hmed_2023_0073 crossref_primary_10_1016_S0140_6736_16_00577_8 crossref_primary_10_1007_s00520_025_09609_0 crossref_primary_10_1186_s40463_016_0155_1 crossref_primary_10_1093_annonc_mdw410 crossref_primary_10_1097_CAD_0000000000000948 crossref_primary_10_1136_bmjopen_2016_011830 crossref_primary_10_1080_2162402X_2020_1845424 crossref_primary_10_3892_ol_2017_7295 crossref_primary_10_1016_j_heliyon_2024_e30723 crossref_primary_10_1038_s41467_024_52694_8 crossref_primary_10_1038_nrclinonc_2015_36 crossref_primary_10_2147_CMAR_S441359 crossref_primary_10_1016_j_clgc_2019_04_012 crossref_primary_10_1111_ecc_13000 crossref_primary_10_1002_cncr_31240 crossref_primary_10_1016_j_canep_2024_102715 crossref_primary_10_1016_j_ijrobp_2016_01_044 crossref_primary_10_3390_biom15060804 crossref_primary_10_1038_bjc_2016_50 crossref_primary_10_1186_s12885_017_3604_y crossref_primary_10_1111_bju_14217 crossref_primary_10_1111_hex_70237 crossref_primary_10_1055_a_1647_9896 crossref_primary_10_1038_s41416_020_0886_7 crossref_primary_10_1177_21925682231218712 crossref_primary_10_3389_fonc_2020_526514 crossref_primary_10_1007_s00038_016_0858_0 crossref_primary_10_1161_CIRCRESAHA_121_318051 crossref_primary_10_1093_annonc_mdw408 crossref_primary_10_1016_j_semcancer_2019_05_013 crossref_primary_10_1371_journal_pone_0171052 crossref_primary_10_1186_s12885_021_08275_9 crossref_primary_10_3390_cancers17081282 crossref_primary_10_7861_clinmedicine_17_4_293 crossref_primary_10_1111_rssc_12566 crossref_primary_10_1186_s44348_024_00014_5 crossref_primary_10_1093_rheumatology_keaf330 crossref_primary_10_1093_bja_aex202 crossref_primary_10_1097_MD_0000000000002529 crossref_primary_10_1186_s12885_019_6184_1 crossref_primary_10_1002_jcsm_12680 crossref_primary_10_1186_s12943_017_0654_3 crossref_primary_10_3389_fphar_2022_887608 crossref_primary_10_1016_j_adro_2025_101806 crossref_primary_10_1016_S0140_6736_21_01895_X crossref_primary_10_1038_s41598_022_21899_6 crossref_primary_10_1136_bmjopen_2021_049087 crossref_primary_10_1016_j_prp_2023_154836 crossref_primary_10_1002_cnr2_1618 crossref_primary_10_3390_cancers14235978 crossref_primary_10_1038_s41419_023_05956_0 crossref_primary_10_1016_S1470_2045_20_30593_3 crossref_primary_10_1007_s00520_021_06105_z crossref_primary_10_5888_pcd14_170201 crossref_primary_10_1038_s41598_017_06207_x crossref_primary_10_1093_jncics_pkz098 crossref_primary_10_1016_j_jaccao_2022_01_096 crossref_primary_10_1016_j_ejso_2018_09_020 crossref_primary_10_1097_MD_0000000000005941 crossref_primary_10_1016_S2213_2600_22_00096_0 crossref_primary_10_1136_bmjopen_2017_016797 crossref_primary_10_1177_2047487319885041 crossref_primary_10_1016_j_jep_2019_02_005 crossref_primary_10_1080_01635581_2025_2514783 crossref_primary_10_1038_s41598_023_37252_4 crossref_primary_10_1007_s11427_022_2218_x crossref_primary_10_1016_j_hpb_2025_07_017 crossref_primary_10_1016_j_jcpo_2018_04_003 crossref_primary_10_1136_bmjopen_2022_066252 crossref_primary_10_1158_2159_8290_CD_22_0876 crossref_primary_10_1007_s00423_020_01920_0 crossref_primary_10_1007_s00103_017_2656_0 crossref_primary_10_7748_cnp_2018_e1484 crossref_primary_10_1002_cnr2_1967 crossref_primary_10_1136_bmj_2022_071726 crossref_primary_10_1017_jns_2023_117 crossref_primary_10_1038_s41598_021_92207_x crossref_primary_10_1259_bjr_20230334 crossref_primary_10_3390_cancers17091534 crossref_primary_10_1016_j_euf_2016_10_005 crossref_primary_10_1097_SPC_0000000000000341 |
| Cites_doi | 10.1016/S0140-6736(10)62231-3 10.1038/sj.bjc.6604595 10.1016/S0140-6736(13)62225-4 10.1038/bjc.1993.60 10.1002/sim.1203 10.1038/sj.bjc.6605402 10.1136/bmj.329.7473.999 10.1038/sj.bjc.6601696 10.1258/jms.2012.012082 10.1111/j.1541-0420.2011.01640.x 10.3109/02841861003691945 10.1007/s10549-008-0100-8 10.1038/bjc.2011.168 10.1111/j.1753-6405.2010.00508.x 10.1038/sj.bjc.6605752 10.1177/1536867X0900900206 10.1016/S1470-2045(09)70028-2 10.1002/sim.3064 10.1109/TAC.1974.1100705 10.1038/sj.bjc.6603668 10.1038/sj.bjc.6605382 |
| ContentType | Journal Article |
| Copyright | 2015 Quaresma et al. Open Access article distributed under the terms of CC BY Quaresma et al. Open Access article distributed under the terms of CC BY Copyright © 2015 Quaresma et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 28, 2015 |
| Copyright_xml | – notice: 2015 Quaresma et al. Open Access article distributed under the terms of CC BY – notice: Quaresma et al. Open Access article distributed under the terms of CC BY – notice: Copyright © 2015 Quaresma et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 28, 2015 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1016/S0140-6736(14)61396-9 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-547X |
| EndPage | 1218 |
| ExternalDocumentID | 3638665781 25479696 10_1016_S0140_6736_14_61396_9 S0140673614613969 1_s2_0_S0140673614613969 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England Wales United Kingdom--UK |
| GeographicLocations_xml | – name: Wales – name: England – name: United Kingdom--UK |
| GrantInformation | Cancer Research UK. |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: C1336/A11700 – fundername: Cancer Research UK grantid: 18525 – fundername: Cancer Research UK grantid: 18348 – fundername: Cancer Research UK grantid: 11700 – fundername: Cancer Research UK grantid: C7923/A18348 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 6I. AAFTH ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c615t-dffc9ef534fdf14e77cef6aa08f99737c04741b10ae9d370f8f58a547631137d3 |
| IEDL.DBID | M0T |
| ISICitedReferencesCount | 372 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000351715100034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Sun Nov 09 11:39:25 EST 2025 Sat Nov 29 14:58:16 EST 2025 Mon Jul 21 06:03:04 EDT 2025 Sat Nov 29 07:24:49 EST 2025 Tue Nov 18 22:36:51 EST 2025 Fri Feb 23 02:24:40 EST 2024 Sun Feb 23 10:18:49 EST 2025 Tue Oct 14 19:34:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9974 |
| Language | English |
| License | Copyright © 2015 Quaresma et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-dffc9ef534fdf14e77cef6aa08f99737c04741b10ae9d370f8f58a547631137d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1016/S0140-6736(14)61396-9 |
| PMID | 25479696 |
| PQID | 1667271697 |
| PQPubID | 40246 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_1671222077 proquest_journals_1667271697 pubmed_primary_25479696 crossref_citationtrail_10_1016_S0140_6736_14_61396_9 crossref_primary_10_1016_S0140_6736_14_61396_9 elsevier_sciencedirect_doi_10_1016_S0140_6736_14_61396_9 elsevier_clinicalkeyesjournals_1_s2_0_S0140673614613969 elsevier_clinicalkey_doi_10_1016_S0140_6736_14_61396_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-03-28 |
| PublicationDateYYYYMMDD | 2015-03-28 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-03-28 day: 28 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Rachet, Maringe, Nur (bib6) 2009; 10 Lawrence, Wallis, Allgood (bib30) 2009; 116 Woods, Rachet, Cooper, Coleman (bib31) 2007; 96 (bib5) 2007 Lambert, Royston (bib17) 2009; 9 Royston, Parmar (bib14) 2002; 21 Perme, Stare, Estève (bib20) 2012; 68 bib11 Coleman, Forman, Bryant (bib33) 2011; 377 (bib4) 1999 (bib18) 2013 Møller, Richards, Hanchett (bib22) 2011; 105 (bib3) 1995 Richards (bib10) 2009; 101 Coleman, Rachet, Woods (bib25) 2004; 90 Borland (bib26) 2014 Pollock, Macfarlane (bib36) 2014 Richards (bib9) 2009; 101 (bib19) 2000 Puliti, Duffy, Miccinesi (bib29) 2012; 19 Coleman (bib1) 2014; 383 Rowan, Rachet, Alexe, Cooper, Coleman (bib27) 2008; 99 Coleman, Babb, Damiecki (bib24) 1999 Sheldon, Cullum, Dawson (bib35) 2004; 329 Nelson, Lambert, Squire, Jones (bib15) 2007; 26 Woods, Rachet, O'Connell (bib32) 2010; 34 Akaike (bib16) 1974; 19 (bib8) 2012 Solomon, Rachet, Whitehead, Coleman (bib12) 2013 (bib21) 2013 Klint, Tryggvadóttir, Bray (bib28) 2010; 49 Swerdlow, Douglas, Vaughan Hudson, Vaughan Hudson (bib23) 1993; 67 (bib34) 2011 (bib13) 2009 (bib2) 2006 Rachet, Ellis, Maringe (bib7) 2010; 103 Nelson (10.1016/S0140-6736(14)61396-9_bib15) 2007; 26 Royston (10.1016/S0140-6736(14)61396-9_bib14) 2002; 21 (10.1016/S0140-6736(14)61396-9_bib19) 2000 Rowan (10.1016/S0140-6736(14)61396-9_bib27) 2008; 99 Pollock (10.1016/S0140-6736(14)61396-9_bib36) Sheldon (10.1016/S0140-6736(14)61396-9_bib35) 2004; 329 Coleman (10.1016/S0140-6736(14)61396-9_bib1) 2014; 383 Coleman (10.1016/S0140-6736(14)61396-9_bib24) 1999 Coleman (10.1016/S0140-6736(14)61396-9_bib25) 2004; 90 (10.1016/S0140-6736(14)61396-9_bib4) 1999 Woods (10.1016/S0140-6736(14)61396-9_bib31) 2007; 96 (10.1016/S0140-6736(14)61396-9_bib21) 2013 (10.1016/S0140-6736(14)61396-9_bib8) 2012 (10.1016/S0140-6736(14)61396-9_bib18) 2013 Woods (10.1016/S0140-6736(14)61396-9_bib32) 2010; 34 Rachet (10.1016/S0140-6736(14)61396-9_bib6) 2009; 10 Richards (10.1016/S0140-6736(14)61396-9_bib10) 2009; 101 Richards (10.1016/S0140-6736(14)61396-9_bib9) 2009; 101 Lambert (10.1016/S0140-6736(14)61396-9_bib17) 2009; 9 Akaike (10.1016/S0140-6736(14)61396-9_bib16) 1974; 19 Møller (10.1016/S0140-6736(14)61396-9_bib22) 2011; 105 Puliti (10.1016/S0140-6736(14)61396-9_bib29) 2012; 19 Solomon (10.1016/S0140-6736(14)61396-9_bib12) (10.1016/S0140-6736(14)61396-9_bib5) 2007 Rachet (10.1016/S0140-6736(14)61396-9_bib7) 2010; 103 Lawrence (10.1016/S0140-6736(14)61396-9_bib30) 2009; 116 Swerdlow (10.1016/S0140-6736(14)61396-9_bib23) 1993; 67 (10.1016/S0140-6736(14)61396-9_bib3) 1995 Borland (10.1016/S0140-6736(14)61396-9_bib26) Klint (10.1016/S0140-6736(14)61396-9_bib28) 2010; 49 Perme (10.1016/S0140-6736(14)61396-9_bib20) 2012; 68 Coleman (10.1016/S0140-6736(14)61396-9_bib33) 2011; 377 25734634 - Nat Rev Clin Oncol. 2015 Apr;12(4):191-2. doi: 10.1038/nrclinonc.2015.36. 25479695 - Lancet. 2015 Mar 28;385(9974):1162-3. doi: 10.1016/S0140-6736(14)62292-3. 25845794 - Lancet. 2015 Mar 28;385(9974):1182. doi: 10.1016/S0140-6736(15)60637-7. |
| References_xml | – volume: 34 start-page: 206 year: 2010 end-page: 213 ident: bib32 article-title: Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980-2002 publication-title: Aust N Z J Public Health – volume: 103 start-page: 446 year: 2010 end-page: 453 ident: bib7 article-title: Socioeconomic inequalities in cancer survival in England after the NHS cancer plan publication-title: Br J Cancer – ident: bib11 article-title: NAEDI Newsletter 2009 – volume: 116 start-page: 179 year: 2009 end-page: 185 ident: bib30 article-title: Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias publication-title: Breast Cancer Res Treat – volume: 21 start-page: 2175 year: 2002 end-page: 2197 ident: bib14 article-title: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects publication-title: Stat Med – year: 2014 ident: bib26 article-title: Half of cancer patients are living for ten years or more: Number classed as having beaten the disease doubles since the 1970s – year: 2013 ident: bib12 article-title: Cancer survival in England: patients diagnosed 2007–2011 and followed up to 2012 – volume: 383 start-page: 564 year: 2014 end-page: 573 ident: bib1 article-title: Cancer survival: global surveillance will stimulate health policy and improve equity publication-title: Lancet – volume: 49 start-page: 632 year: 2010 end-page: 643 ident: bib28 article-title: Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006 publication-title: Acta Oncol – year: 2006 ident: bib2 article-title: Designed to tackle cancer in Wales: a Welsh assembly government policy statement: Welsh assembly government – volume: 9 start-page: 265 year: 2009 end-page: 290 ident: bib17 article-title: Further development of flexible parametric models for survival analysis publication-title: Stata J – volume: 105 start-page: 170 year: 2011 end-page: 176 ident: bib22 article-title: Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates publication-title: Br J Cancer – year: 1999 ident: bib4 publication-title: Challenging cancer – year: 2000 ident: bib19 publication-title: The NHS Cancer Plan: a plan for investment, a plan for reform – volume: 10 start-page: 351 year: 2009 end-page: 369 ident: bib6 article-title: Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England publication-title: Lancet Oncol – year: 2007 ident: bib5 publication-title: Cancer Reform Strategy – year: 2012 ident: bib8 publication-title: Improving outcomes: a strategy for cancer—second annual report 2012 – year: 2013 ident: bib18 publication-title: STATA statistical software – volume: 101 start-page: S1 year: 2009 end-page: S4 ident: bib10 article-title: The National Awareness and Early Diagnosis Initiative in England: assembling the evidence publication-title: Br J Cancer – volume: 99 start-page: S75 year: 2008 end-page: S77 ident: bib27 article-title: Survival from prostate cancer in England and Wales up to 2001 publication-title: Br J Cancer – volume: 26 start-page: 5486 year: 2007 end-page: 5498 ident: bib15 article-title: Flexible parametric models for relative survival, with application in coronary heart disease publication-title: Stat Med – year: 1995 ident: bib3 publication-title: A policy framework for commissioning cancer services (Calman-Hine report) – year: 2013 ident: bib21 publication-title: Cancer statistics: registrations of cancer diagnosed in 2011, England. Series MB1 no. 42 – volume: 101 start-page: S125 year: 2009 end-page: S129 ident: bib9 article-title: The size of the prize for earlier diagnosis of cancer in England publication-title: Br J Cancer – volume: 19 start-page: 716 year: 1974 end-page: 723 ident: bib16 article-title: A new look at the statistical model identification publication-title: IEEE Trans Automat Contr – volume: 19 start-page: 42 year: 2012 end-page: 56 ident: bib29 article-title: Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review publication-title: J Med Screen – volume: 96 start-page: 1135 year: 2007 end-page: 1138 ident: bib31 article-title: Predicted trends in long-term breast cancer survival in England and Wales publication-title: Br J Cancer – year: 1999 ident: bib24 publication-title: Cancer survival trends in England and Wales 1971–1995: deprivation and NHS region. (studies on medical and population subjects no. 61) – year: 2009 ident: bib13 article-title: Life tables for England and Wales by sex, calendar period, region and deprivation – year: 2014 ident: bib36 article-title: Opting out of care data is not the answer – volume: 377 start-page: 127 year: 2011 end-page: 138 ident: bib33 article-title: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data publication-title: Lancet – year: 2011 ident: bib34 article-title: Lung cancer—the diagnosis and treatment of lung cancer – volume: 67 start-page: 326 year: 1993 end-page: 329 ident: bib23 article-title: Completeness of cancer registration in England and Wales: an assessment based on 2,145 patients with Hodgkin's disease independently registered by the British National Lymphoma Investigation publication-title: Br J Cancer – volume: 90 start-page: 1367 year: 2004 end-page: 1373 ident: bib25 article-title: Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001 publication-title: Br J Cancer – volume: 68 start-page: 113 year: 2012 end-page: 120 ident: bib20 article-title: On estimation in relative survival publication-title: Biometrics – volume: 329 start-page: 999 year: 2004 end-page: 1003 ident: bib35 article-title: What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews publication-title: BMJ – volume: 377 start-page: 127 year: 2011 ident: 10.1016/S0140-6736(14)61396-9_bib33 article-title: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data publication-title: Lancet doi: 10.1016/S0140-6736(10)62231-3 – year: 2012 ident: 10.1016/S0140-6736(14)61396-9_bib8 – volume: 99 start-page: S75 issue: suppl 1 year: 2008 ident: 10.1016/S0140-6736(14)61396-9_bib27 article-title: Survival from prostate cancer in England and Wales up to 2001 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604595 – volume: 383 start-page: 564 year: 2014 ident: 10.1016/S0140-6736(14)61396-9_bib1 article-title: Cancer survival: global surveillance will stimulate health policy and improve equity publication-title: Lancet doi: 10.1016/S0140-6736(13)62225-4 – volume: 67 start-page: 326 year: 1993 ident: 10.1016/S0140-6736(14)61396-9_bib23 article-title: Completeness of cancer registration in England and Wales: an assessment based on 2,145 patients with Hodgkin's disease independently registered by the British National Lymphoma Investigation publication-title: Br J Cancer doi: 10.1038/bjc.1993.60 – year: 2013 ident: 10.1016/S0140-6736(14)61396-9_bib21 – year: 2007 ident: 10.1016/S0140-6736(14)61396-9_bib5 – volume: 21 start-page: 2175 year: 2002 ident: 10.1016/S0140-6736(14)61396-9_bib14 article-title: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects publication-title: Stat Med doi: 10.1002/sim.1203 – volume: 101 start-page: S125 issue: suppl 2 year: 2009 ident: 10.1016/S0140-6736(14)61396-9_bib9 article-title: The size of the prize for earlier diagnosis of cancer in England publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605402 – volume: 329 start-page: 999 year: 2004 ident: 10.1016/S0140-6736(14)61396-9_bib35 article-title: What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews publication-title: BMJ doi: 10.1136/bmj.329.7473.999 – year: 1995 ident: 10.1016/S0140-6736(14)61396-9_bib3 – ident: 10.1016/S0140-6736(14)61396-9_bib26 – volume: 90 start-page: 1367 year: 2004 ident: 10.1016/S0140-6736(14)61396-9_bib25 article-title: Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601696 – volume: 19 start-page: 42 issue: suppl 1 year: 2012 ident: 10.1016/S0140-6736(14)61396-9_bib29 article-title: Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review publication-title: J Med Screen doi: 10.1258/jms.2012.012082 – year: 2013 ident: 10.1016/S0140-6736(14)61396-9_bib18 – volume: 68 start-page: 113 year: 2012 ident: 10.1016/S0140-6736(14)61396-9_bib20 article-title: On estimation in relative survival publication-title: Biometrics doi: 10.1111/j.1541-0420.2011.01640.x – volume: 49 start-page: 632 year: 2010 ident: 10.1016/S0140-6736(14)61396-9_bib28 article-title: Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964–2003 followed up to the end of 2006 publication-title: Acta Oncol doi: 10.3109/02841861003691945 – volume: 116 start-page: 179 year: 2009 ident: 10.1016/S0140-6736(14)61396-9_bib30 article-title: Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-008-0100-8 – year: 2000 ident: 10.1016/S0140-6736(14)61396-9_bib19 – volume: 105 start-page: 170 year: 2011 ident: 10.1016/S0140-6736(14)61396-9_bib22 article-title: Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates publication-title: Br J Cancer doi: 10.1038/bjc.2011.168 – volume: 34 start-page: 206 year: 2010 ident: 10.1016/S0140-6736(14)61396-9_bib32 article-title: Differences in breast cancer incidence in Australia and England by age, extent of disease and deprivation status: women diagnosed 1980-2002 publication-title: Aust N Z J Public Health doi: 10.1111/j.1753-6405.2010.00508.x – volume: 103 start-page: 446 year: 2010 ident: 10.1016/S0140-6736(14)61396-9_bib7 article-title: Socioeconomic inequalities in cancer survival in England after the NHS cancer plan publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605752 – ident: 10.1016/S0140-6736(14)61396-9_bib12 – volume: 9 start-page: 265 year: 2009 ident: 10.1016/S0140-6736(14)61396-9_bib17 article-title: Further development of flexible parametric models for survival analysis publication-title: Stata J doi: 10.1177/1536867X0900900206 – ident: 10.1016/S0140-6736(14)61396-9_bib36 – volume: 10 start-page: 351 year: 2009 ident: 10.1016/S0140-6736(14)61396-9_bib6 article-title: Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70028-2 – year: 1999 ident: 10.1016/S0140-6736(14)61396-9_bib4 – volume: 26 start-page: 5486 year: 2007 ident: 10.1016/S0140-6736(14)61396-9_bib15 article-title: Flexible parametric models for relative survival, with application in coronary heart disease publication-title: Stat Med doi: 10.1002/sim.3064 – year: 1999 ident: 10.1016/S0140-6736(14)61396-9_bib24 – volume: 19 start-page: 716 year: 1974 ident: 10.1016/S0140-6736(14)61396-9_bib16 article-title: A new look at the statistical model identification publication-title: IEEE Trans Automat Contr doi: 10.1109/TAC.1974.1100705 – volume: 96 start-page: 1135 year: 2007 ident: 10.1016/S0140-6736(14)61396-9_bib31 article-title: Predicted trends in long-term breast cancer survival in England and Wales publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603668 – volume: 101 start-page: S1 issue: suppl 2 year: 2009 ident: 10.1016/S0140-6736(14)61396-9_bib10 article-title: The National Awareness and Early Diagnosis Initiative in England: assembling the evidence publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605382 – reference: 25845794 - Lancet. 2015 Mar 28;385(9974):1182. doi: 10.1016/S0140-6736(15)60637-7. – reference: 25479695 - Lancet. 2015 Mar 28;385(9974):1162-3. doi: 10.1016/S0140-6736(14)62292-3. – reference: 25734634 - Nat Rev Clin Oncol. 2015 Apr;12(4):191-2. doi: 10.1038/nrclinonc.2015.36. |
| SSID | ssj0004605 |
| Score | 2.621035 |
| Snippet | Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key insight into the... Summary Background Assessment of progress in cancer control at the population level is increasingly important. Population-based survival trends provide a key... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1206 |
| SubjectTerms | Adolescent Adult Age Age Distribution Aged Aged, 80 and over Cancer England - epidemiology Female Humans Incidence Internal Medicine Male Medical prognosis Mens health Mortality Mortality - trends Neoplasms - mortality Observational studies Pancreatic cancer Patients Population studies Public concern Public health Registries Sex Distribution Survival Survival Analysis Trends Wales - epidemiology Womens health Young Adult |
| Title | 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673614613969 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673614613969 https://dx.doi.org/10.1016/S0140-6736(14)61396-9 https://www.ncbi.nlm.nih.gov/pubmed/25479696 https://www.proquest.com/docview/1667271697 https://www.proquest.com/docview/1671222077 |
| Volume | 385 |
| WOSCitedRecordID | wos000351715100034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250913 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYhhAS4mN8FUZlJB5AwlucuHHMC4JpEw-0VKOMvkWJP9BQlZamReKv4l_kznHSl44h8XJSkjvbSs53v9jnO0JeYIoUY6VhkVYFEzrTrDQlZwa36NBlKB9NeP5RjkbZdKrGYcGtDmGVrU30htrMNa6RH_EU9wx5quTbxQ-GVaNwdzWU0NghexygNVYwGEaTbecifYj75gTP0efu5ksuXoFPUylTl_mmy7Cn90Gnd_539HfJ7YA-6btGXe6Ra7baJzeGYX99n9xqVvFoczjpPvkNo_8Fc4GufOgsvahoUVGfYZHOHa3XYGhAVSkgX1rMZlSjDi1rCoOCP25rgNtsuArzfY2rqw37N9s8habwGqM6gzx2E4qLeJav4MTq15QryRkiiTe0oIuu8BhDRwztYJ7cB-TL6cnk-AMLJR6YBii1YsY5rawbJMIZx4WVUluXFkWUOaVkInUkAPKUPCqsMomMXOYGWTEQYBU5T6RJHpLdal7Zx4Q6AB7cORMb5URmXYmp7uVA6NLBL1QiekS0HzfXIf85luGY5VsC3bjIvU7kqkcOO7FFkwDkKoG01Zy8Pd0K9jgHF3WVoNwmaOtgVeqc53WcR400CmNNdhAFyayTDMCpAUT_0ulBq7D5pp9OW3vkefcY7A5uJhWVna-RR3LAlpEEnkfNpOjeTwwfCLMuPfl740_JTVCaAUb0xdkB2V0t1_YZua5_ri7qZZ_syLNzpFPpaQY0O-Z9svf-ZDQ-6-NUb-gEaTz09JOnY6Ry_AcI_lLr |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3ZbtNAcFUKAiTEUa5AgUUCCSSWeu2N14uEEAKqVk0iJAr0bVnvgYoiJ8QJqD8Fv8iMr7yklJc-8Gh7ZtYaz-XdOQh5hC1SnJeORVYZJmxmWe5yzhwe0aHLUFU24aeBHI2ygwP1fo38amthMK2ytYmVoXYTi3vkWzzFM0OeKvlq-p3h1Cg8XW1HaNRiseePfsIvW_ly9y1838dxvP1u_80Oa6YKMAvee85cCFb50E9EcIELL6X1ITUmyoJSMpE2EuBlcx4Zr1wio5CFfmb6AhSR80S6BOieIWcFeEKcmDCMh6vqMKuU-mXF0NaH7uYTLp6CD1UpU8f5wuNi3crnbV_537h1lVxuomv6ulaHa2TNFxvk_LDJH9ggl-pdSloXX10nv4FbR_CadF6lBtPDgpqCVh0k6STQcgGGFFSRQmRPzXhMLerIrKTAhBwIOoB2Syjjvi1w97gG_-rrp0AKrzFrtcHHZZrhKRXIZ3DS5TPKleQMI6UX1NBpN1iNYaABdLAP8A3y8VTYd5OsF5PC3yY0QGDFQ3CxU0FkPuTYyl_2hc0D_CImokdEK0zaNv3dcczIWK9I5ONCVzKoVY8879CmdYOTkxDSVlJ1W70L_kaDCz4JUa5C9GVjNUvNdRnrqMZGZJw5D6iAmXWYTWBYB3z_suhmqyB6uU6nHT3ysHsMdhUPy0zhJwuEkRxi50gCzK1aCTv-xPCBsKvUnb8Tf0Au7OwPB3qwO9q7Sy6CAPUxezHONsn6fLbw98g5-2N-WM7uV2aEki-nrYl_ALhwpnU |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3ZbtNAcFUKqpAQR7kCBRYJJJDYxmuvvV4khBAlomobKlGgb1t7D1QUOSFOQP0q3vk6ZnzlJaW89IFH2zOz1ngu785ByBNskWKdtCwwKmPCpIblNufM4hEdugxVZRN-3pXDYXp4qPZXyO-2FgbTKlubWBlqOza4R97nCZ4Z8kTJvm_SIva3Bq8n3xlOkMKT1nacRi0iO-7kJ_y-la-2t-BbPw3DwbuDt-9ZM2GAGfDkM2a9N8r5OBLeei6clMb5JMuC1CslI2kCAR4350HmlI1k4FMfp1ksQCk5j6SNgO4FclGKWKB27YUfltVkVun1i-qh_sfu5jMunoM_VQlTp_nF0-Leyv8Nrv3PnLtOrjZRN31Tq8kNsuKKdbK21-QVrJMr9e4lrYuybpJfwLkTeE06q1KG6XFBs4JWnSXp2NNyDgYWVJRCxE-z0Yga1J1pSYEhORC0AG0XUJn9Nsdd5Rr8q6ufAim8xmzWBh-XaYaqVCBfwHmXLyhXkjOMoF7SjE66gWsMAxCgg_2Bb5FP58K-22S1GBfuLqEeAi7uvQ2t8iJ1PscW_zIWJvfw6xiJHhGtYGnT9H3H8SMjvSTBjwtdyaNWPbLZoU3qxidnISSt1Oq2qhf8kAbXfBaiXIboysaalprrMtRBjY3IOIseUAEz7TCbgLEOBP9l0Y1WWfRinU5TeuRx9xjsLR6iZYUbzxFGcoipAwkwd2qF7PgTwgfCblP3_k78EVkDBdS728Od--QyyE-MSY1hukFWZ9O5e0AumR-z43L6sLIolBydtyL-AVAnr0E |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=40-year+trends+in+an+index+of+survival+for+all+cancers+combined+and+survival+adjusted+for+age+and+sex+for+each+cancer+in+England+and+Wales%2C+1971%E2%80%932011%3A+a+population-based+study&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Quaresma%2C+Manuela%2C+Ms&rft.au=Coleman%2C+Michel+P%2C+Prof&rft.au=Rachet%2C+Bernard%2C+FFPH&rft.date=2015-03-28&rft.issn=0140-6736&rft.volume=385&rft.issue=9974&rft.spage=1206&rft.epage=1218&rft_id=info:doi/10.1016%2FS0140-6736%2814%2961396-9&rft.externalDBID=ECK1-s2.0-S0140673614613969&rft.externalDocID=1_s2_0_S0140673614613969 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673615X61344%2Fcov150h.gif |